Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNkarta Inc

Nkarta Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.48 USD 0.13 ( 9.63%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1150579
Market Cap
206.28M

Momentum Score

…

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.32
Low
1.51
High
52 Week Price Range
1.70
Low
3.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.35
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-36.22M
Debt / Equity
0.24
ROE
-38.76%
Net Debt
36.79M
ROCE
-27.25%
Diluted EPS TTM
-1.57

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -104.08M -108.79M -117.50M -113.84M -86.08M
Net income -104.08M -108.79M -117.50M -119.42M -83.95M
Selling general administrative 31.57M 31.45M 34.88M 28.06M 23.02M
Selling and marketing expenses - - 5.30M - -
Gross profit -9.19M -9.15M -5.87M - -
Reconciled depreciation 9.19M 9.15M 4.35M 2.64M 1.76M
Ebit -104.08M -108.79M -126.35M -121.59M -88.19M
Ebitda -94.89M -99.64M -120.48M -118.95M -86.43M
Depreciation and amortization 9.19M 9.15M 5.87M 2.64M 1.76M
Non operating income net other - - - 5.12M 0.35M
Operating income -121.21M -128.19M -131.65M -118.95M -86.43M
Other operating expenses 121.21M 128.19M 131.65M 118.95M 86.43M
Interest expense - - - 5.59M 2.11M
Interest income 15.49M 19.32M 13.54M 5.59M 0.37M
Net interest income 15.49M 19.32M 13.54M 5.59M 0.37M
Income tax expense - - 5.30M 5.59M -2.13M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 112.01M 128.19M 125.78M 118.95M 86.43M
Cost of revenue 9.19M 9.15M 5.87M - -
Total other income expense net 17.12M 19.40M 14.15M 5.12M 0.35M
Net income from continuing ops -104.08M -108.79M -122.33M -113.84M -86.08M
Net income applicable to common shares - - - -113.84M -86.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 404.21M 501.20M 378.88M 472.94M 273.90M
Other current assets 4.23M 5.78M 4.68M 2.93M 3.15M
Total liab 91.88M 93.23M 105.60M 100.73M 22.94M
Total stockholder equity 312.32M 407.98M 273.29M 372.21M 250.97M
Other current liab 13.29M 12.23M 13.60M 11.79M 6.88M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -648.31M -544.22M -435.43M -317.93M -204.10M
Other liab - - - - 0.02M
Other assets - - - 4.59M 3.59M
Cash 39.63M 27.87M 31.04M 37.49M 60.82M
Total current liabilities 22.27M 18.92M 23.33M 17.80M 10.48M
Net debt 36.79M 52.40M 57.30M 49.69M -48.36M
Short term debt 6.89M 6.05M 6.07M 4.25M 2.48M
Short long term debt total 76.42M 80.27M 88.34M 87.18M 12.46M
Other stockholder equity 960.22M 951.52M 708.71M 690.81M 455.21M
Property plant equipment - - - 61.91M 12.86M
Total current assets 282.51M 273.34M 253.07M 354.89M 240.19M
Long term investments 16.11M 110.39M - - -
Net tangible assets - - - 372.21M 250.97M
Short term investments 236.65M 239.48M 217.15M 314.65M 177.27M
Net receivables 2.00M 0.20M 0.20M - -
Accounts payable 2.09M 0.64M 3.67M 1.76M 1.11M
Accumulated other comprehensive income 0.41M 0.67M 0.01M -0.68M -0.15M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -317.93M -204.10M
Non currrent assets other 4.44M 6.80M 3.80M 10.39M 9.18M
Non current assets total 121.70M 227.87M 125.81M 118.05M 33.72M
Capital lease obligations 76.42M 80.27M 88.34M 82.93M 12.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 101.53M -129.56M 67.92M -137.58M 37.56M
Change to liabilities - - - 2.76M 2.79M
Total cashflows from investing activities 100.32M -129.56M 79.02M -184.69M 32.53M
Total cash from financing activities 0.14M 226.08M 0.69M 219.01M 1.20M
Change to operating activities - - - 30.98M -4.43M
Net income -104.08M -108.79M -117.50M -113.84M -86.08M
Change in cash 11.76M -3.17M -6.45M -22.68M -34.19M
Begin period cash flow 30.62M 33.78M 40.24M 62.91M 97.11M
End period cash flow 42.38M 30.62M 33.78M 40.24M 62.91M
Total cash from operating activities -88.70M -99.70M -86.16M -57.00M -67.93M
Issuance of capital stock 0.00M 225.07M -0.05M 217.17M 0.00M
Depreciation 4.61M 2.24M 5.87M 2.64M 1.76M
Sale purchase of stock - - - 1.84M 1.48M
Other cashflows from financing activities 0.14M 1.01M 0.69M 1.84M 1.20M
Change to netincome - - - 16.86M 14.43M
Capital expenditures 1.21M 4.41M 28.15M 47.11M 5.03M
Cash flows other operating - - - 38.16M -1.28M
Cash and cash equivalents changes - - - -22.68M -34.19M
Change in working capital -0.43M -12.16M 10.93M 33.74M -1.64M
Stock based compensation 8.56M 16.73M 17.20M 16.86M 14.46M
Other non cash items 2.65M 2.29M -2.65M 3.61M 0.34M
Free cash flow -89.91M -104.11M -114.31M -104.11M -72.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NKTX
Nkarta Inc		 0.13
9.63%		 1.48 - - 1000000.00 0.84 1000000.00 0.95
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nkarta Inc

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

1150 Veterans Boulevard, South San Francisco, CA, United States, 94080

925 407 1049

https://www.nkartatx.com

106

Name Title Year Born
Mr. Paul J. Hastings CEO, Pres & Director 1960
Dr. Nadir Mahmood Ph.D. Chief Financial & Bus. Officer 1979
Dr. Ralph Brandenberger Ph.D. Chief Technical Officer 1969
Dr. James Trager Ph.D., Ph.D. Chief Scientific Officer 1964
Ms. Yvonne Li M.B.A. Chief Admin. Officer 1960
Mr. Greg Mann VP of Public Affairs and Investor Relations NA
Dr. Alicia J. Hager Chief Legal Officer & Corp. Sec. 1970
Dr. David R. Shook M.D. VP of Clinical Devel. NA
Mr. Paul J. Hastings CEO, President & Director 1960
Dr. Alicia J. Hager Chief Legal Officer & Corporate Secretary 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…